Edgestream Partners L.P. bought a new position in 10x Genomics (NASDAQ:TXG – Free Report) during the 1st quarter, Holdings Channel.com reports. The firm bought 58,083 shares of the company’s stock, valued at approximately $1,233,000.
Several other hedge funds also recently made changes to their positions in TXG. Geneos Wealth Management Inc. bought a new stake in 10x Genomics during the 4th quarter valued at $38,000. Larson Financial Group LLC increased its position in shares of 10x Genomics by 164.4% in the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after acquiring an additional 1,470 shares during the period. Fifth Third Bancorp bought a new position in shares of 10x Genomics during the first quarter valued at about $50,000. Van ECK Associates Corp boosted its holdings in shares of 10x Genomics by 85.9% during the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after purchasing an additional 1,695 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of 10x Genomics by 203.9% during the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after purchasing an additional 5,025 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at 10x Genomics
In other 10x Genomics news, CEO Serge Saxonov sold 30,000 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $34.44, for a total value of $1,033,200.00. Following the completion of the transaction, the chief executive officer owned 1,108,380 shares in the company, valued at approximately $38,172,607.20. This represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Shehnaaz Suliman sold 5,723 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $32.63, for a total value of $186,741.49. Following the transaction, the director directly owned 31,722 shares of the company’s stock, valued at $1,035,088.86. This represents a 15.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 91,309 shares of company stock valued at $2,581,357. Company insiders own 8.84% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Report on 10x Genomics
10x Genomics Price Performance
Shares of TXG opened at $47.01 on Tuesday. 10x Genomics has a one year low of $11.16 and a one year high of $50.34. The company has a 50-day simple moving average of $37.55 and a two-hundred day simple moving average of $26.90. The firm has a market capitalization of $5.97 billion, a PE ratio of -276.53 and a beta of 2.03.
10x Genomics (NASDAQ:TXG – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.19. 10x Genomics had a negative return on equity of 2.86% and a negative net margin of 3.55%.The business had revenue of $150.84 million for the quarter, compared to analysts’ expectations of $146.41 million. During the same period in the previous year, the firm posted ($0.28) EPS. The business’s revenue was up 9.4% on a year-over-year basis. Analysts expect that 10x Genomics will post -0.78 EPS for the current fiscal year.
10x Genomics Company Profile
10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.
Read More
- Five stocks we like better than 10x Genomics
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG – Free Report).
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
